Recent Research

Abel GA, et al. – Research presented at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition showed a shared care approach after allogeneic hematopoietic cell transplantation did not compromise non-relapse mortality and may be associated with improved quality of life.

Salit RB, et al. – The American Society of Transplantation and Cellular Therapy (ASTCT) gathered a panel of experts in survivorship, rehabilitation, and psychological and logistical challenges to review research about patients with hematologic cancers returning to work post-hematopoietic cell transplantation. These experts produced an evidence-based guidance document to assist healthcare providers in navigating the barriers of post-transplant care and optimizing collaboration to help patients achieve this quality-of-life milestone.

Steffens K, et al. – Research shared at the 2022 Tandem Meetings of the ASTCT and CIBMTR presents survey outcomes from community hematology/oncology physicians regarding the strength of their relationships with local transplant centers. Community physicians with a lower self-rated relationship strength with transplant centers reported less support for early HCT treatment behaviors and lower confidence in managing patients post-transplant.

Zeiser R, et al. Blood – The latest research in cellular therapies, antibody-based treatments, and tyrosine kinase inhibitor (TKI)-based approaches to enhance GVL effects are outlined in articles published in a special edition of Blood.